{"id":2092,"date":"2022-09-12T08:32:37","date_gmt":"2022-09-12T08:32:37","guid":{"rendered":"https:\/\/neuropediatoolbox.org\/?p=2092"},"modified":"2026-08-11T10:17:21","modified_gmt":"2026-08-11T10:17:21","slug":"palivizumab-en-ninos-con-enfermedades-neurologicas","status":"publish","type":"post","link":"https:\/\/neuropediatoolkit.org\/fr\/palivizumab-en-ninos-con-enfermedades-neurologicas\/","title":{"rendered":"Profilaxis VRS en ni\u00f1os con enfermedades neurol\u00f3gicas."},"content":{"rendered":"<p>Se recomienda la profilaxis con nirsevimab, para la prevenci\u00f3n de las enfermedades graves del tracto respiratorio inferior producidas por VRS, durante los per\u00edodos previstos de riesgo de infecci\u00f3n por VRS, en:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pacientes menores de 24 meses de edad afectos de enfermedades neuromusculares con hipoton\u00eda marcada y\/o debilidad muscular respiratoria. <\/li>\n\n\n\n<li>Pacientes menores de 24 meses afectos de encefalopat\u00edas est\u00e1ticas o<br>maladies chromosomiques qui pr\u00e9sentent une hypotonie marqu\u00e9e (Ex : Prader Willi). <\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/nirsevimab-infov2-sep2025.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of nirsevimab-infov2-sep2025.\"><\/object><a id=\"wp-block-file--media-22fd4c1b-a67d-477d-a8b2-c3d53671d872\" href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/nirsevimab-infov2-sep2025.pdf\">nirsevimab-infov2-sep2025<\/a><a href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/nirsevimab-infov2-sep2025.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-22fd4c1b-a67d-477d-a8b2-c3d53671d872\">D\u00e9charge<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/NirsevimabActualizacion.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of NirsevimabActualizacion.\"><\/object><a id=\"wp-block-file--media-05eb5b09-7881-4d43-ba5a-2addfb0966ca\" href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/NirsevimabActualizacion.pdf\">NirsevimabActualizacion<\/a><a href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/NirsevimabActualizacion.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-05eb5b09-7881-4d43-ba5a-2addfb0966ca\">D\u00e9charge<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos.\"><\/object><a id=\"wp-block-file--media-53309992-92a1-4516-a3d2-9bbb5f918a81\" href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos.pdf\">RECOMMANDATIONS_SENEP_use_PALIVIZUMAB_corrected_by_AE_with_logos<\/a><a href=\"https:\/\/neuropediatoolkit.org\/wp-content\/uploads\/2022\/09\/RECOMENDACIONES_SENEP_uso_PALIVIZUMAB_corregido_por_AE_con_logos.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-53309992-92a1-4516-a3d2-9bbb5f918a81\">D\u00e9charge<\/a><\/div>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Se recomienda la profilaxis con nirsevimab, para la prevenci\u00f3n de las enfermedades graves del tracto respiratorio inferior producidas por VRS, durante los per\u00edodos previstos de riesgo de infecci\u00f3n por VRS, en:<\/p>","protected":false},"author":1,"featured_media":2096,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-2092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aspectos-pediatricos","entry"],"_links":{"self":[{"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/posts\/2092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/comments?post=2092"}],"version-history":[{"count":4,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/posts\/2092\/revisions"}],"predecessor-version":[{"id":8507,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/posts\/2092\/revisions\/8507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/media\/2096"}],"wp:attachment":[{"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/media?parent=2092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/categories?post=2092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neuropediatoolkit.org\/fr\/wp-json\/wp\/v2\/tags?post=2092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}